Skip to Content
Global News Select

Denali Therapeutics Shares Fall After ALS Treatment Misses Primary Endpoint

By Sabela Ojea


Shares of Denali Therapeutics on Friday fell after the company said the Phase 2 Himalaya study to treat patients with its amyotrophic lateral sclerosis (ALS) with an oral brain-penetrant inhibitor missed the primary endpoint.

In recent trading, shares were down 7.4% to $17.01. The stock has dropped 22% since the beginning of the year, and 45% in the past 12 months.

The biotechnology company said the SAR443820/DNL788 inhibitor, co-developed with Sanofi, didn't meet the endpoint of change in ALS functional rating scale-revised.

Sanofi will continue to conduct the K2 Phase 2 study of SAR443820/DNL788 in participants with multiple sclerosis.


Write to Sabela Ojea at; @sabelaojeaguix


(END) Dow Jones Newswires

February 16, 2024 11:40 ET (16:40 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Market Updates

Sponsor Center